Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment of COVID-19

Adnan Shah, Adnan Shah

No abstract available

Keywords: COVID-19; NLRP3 inflammasome; SARS-CoV; cytokines; viroporins.

Figures

Figure 1
Figure 1
Schematic representation of SARS-CoV viroporin-mediated NLRP3 inflammasome activation, its inhibitors (shown with asterisks) and downstream inflammatory cascades leading to inflammation and cell death. Genes (italicized) in empty boxes, respective proteins in gray boxes.

References

    1. Zaki AM, Van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. (2012) 367:1814–20. 10.1056/NEJMoa1211721
    1. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe L, et al. . Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. (2020) 105949. 10.1016/j.ijantimicag.2020.105949. [Epub ahead of print].
    1. Tan YJ, Lim SG, Hong W. Characterization of viral proteins encoded by the SARS-coronavirus genome. Antiviral Res. (2005) 65:69–78. 10.1016/j.antiviral.2004.10.001
    1. Torres J, Maheswari U, Parthasarathy K, Ng L, Liu DX, Gong X. Conductance and amantadine binding of a pore formed by a lysine-flanked transmembrane domain of SARS coronavirus envelope protein. Protein Sci. (2007) 16:2065–71. 10.1110/ps.062730007
    1. Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. (2020) 5:562–9. 10.1038/s41564-020-0688-y
    1. Nieva JL, Madan V, Carrasco L. Viroporins: structure and biological functions. Nat Rev Microbiol. (2012) 10:563–74. 10.1038/nrmicro2820
    1. Siu KL, Yuen KS, Castano-Rodriguez C, Ye ZW, Yeung ML, Fung SY, et al. . Severe acute respiratory syndrome Coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of ASC. FASEB J. (2019) 33:8865–77. 10.1096/fj.201802418R
    1. Castaño-Rodriguez C, Honrubia JM, Gutiérrez-Álvarez J, DeDiego ML, Nieto-Torres JL, Jimenez-Guardeno JM, et al. . Role of severe acute respiratory syndrome coronavirus viroporins E, 3a, and 8a in replication and pathogenesis. MBio. (2018) 9:e02325-17. 10.1128/mBio.02325-17
    1. DeDiego ML, Nieto-Torres JL, Regla-Nava JA, Jimenez-Guardeno JM, Fernandez-Delgado R, Fett C, et al. Inhibition of NF-kB-mediated inflammation in severe acute respiratory syndrome coronavirus-infected mice increases survival. J Virol. (2014) 88:913–24. 10.1128/JVI.02576-13
    1. Nieto-Torres JL, Verdiá-Báguena C, Jimenez-Guardeño JM, Regla-Nava JA, Castano-Rodriguez C, Fernandez-Delgado R, et al. . Severe acute respiratory syndrome coronavirus E protein transports calcium ions and activates the NLRP3 inflammasome. Virology. (2015) 485:330–9. 10.1016/j.virol.2015.08.010
    1. Elliott EI, Sutterwala FS. Initiation and perpetuation of NLRP3 inflammasome activation and assembly. Immunol Rev. (2015) 265:35–52. 10.1111/imr.12286
    1. Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol. (2013) 13:397–411. 10.1038/nri3452
    1. Mangan MSJ, Olhava EJ, Roush WR, Seidel HM, Glick GD, Latz E. Targeting the NLRP3 inflammasome in inflammatory diseases. Nat Rev Drug Discov. (2018) 17:588–606. 10.1038/nrd.2018.97
    1. Yue Y, Nabar NR, Shi CS, Kanenyeva O, Xiao X, Hwang IY, et al. . SARS-coronavirus open reading frame-3a drives multimodal necrotic cell death. Cell Death Dis. (2018) 9:904. 10.1038/s41419-018-0917-y
    1. He L, Ding Y, Zhang Q, Chen X, He Y, Shen H, et al. . Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS. J Pathol. (2006) 210:288–97. 10.1002/path.2067
    1. Nieto-Torres JL, DeDiego ML, Verdiá-Báguena C, Jimenez-Guardeno JM, Regla-Nava JA, Fernandez-Delgado R, et al. . Severe acute respiratory syndrome coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis. PLoS Pathog. (2014) 10:e1004077. 10.1371/journal.ppat.1004077
    1. Wilson L, Gage P, Ewart G. Hexamethylene amiloride blocks E protein ion channels and inhibits coronavirus replication. Virology. (2006) 353:294–306. 10.1016/j.virol.2006.05.028
    1. Chen IY, Moriyama M, Chang MF, Ichinohe T. Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome. Front Microbiol. (2019) 10:1–9. 10.3389/fmicb.2019.00050
    1. Costa LS, Outlioua A, Anginot A, Akarid K, Arnoult D. RNA viruses promote activation of the NLRP3 inflammasome through cytopathogenic effect-induced potassium efflux. Cell Death Dis. (2019) 10:346. 10.1038/s41419-019-1579-0
    1. Jones HD, Crother TR, Gonzalez-Villalobos RA, Jupelli M, Chen S, Dagvadorj J, et al. . The NLRP3 inflammasome is required for the development of hypoxemia in LPS/mechanical ventilation acute lung injury. Am J Respir Cell Mol Biol. (2014) 50:270–80. 10.1165/rcmb.2013-0087OC
    1. Li D, Ren W, Jiang Z, Zhu L. Regulation of the NLRP3 inflammasome and macrophage pyroptosis by the p38 MAPK signaling pathway in a mouse model of acute lung injury. Mol Med Rep. (2018) 18:4399–409. 10.3892/mmr.2018.9427
    1. Grailer JJ, Canning BA, Kalbitz M, Haggadone MD, Dhond RM, Andjelkovic AV, et al. . Critical Role for the NLRP3 Inflammasome during acute lung injury. J Immunol. (2014) 192:5974–83. 10.4049/jimmunol.1400368
    1. Mathay MA, Zemans RL. The acute respiratory distress syndrome: pathogenesis and treatment. Annu Rev Pathol. (2011) 6:147–63. 10.1146/annurev-pathol-011110-130158
    1. DElia RV, Harrison K, Oyston PC, Lukaszewski RA, Clark GC. Targeting the “cytokine storm” for therapeutic benefit. Clin Vaccine Immunol. (2013) 20:319–27. 10.1128/CVI.00636-12
    1. Huppert LA, Mathay MA, Ware LB. Pathogenesis of acute respiratory distress syndrome. Semin Respir Crit Care Med. (2019) 40:31–9. 10.1055/s-0039-1683996
    1. Han S, Mallampalli RK. The acute respiratory distress syndrome: from mechanism to translation. J Immunol. (2015) 194:855–60. 10.4049/jimmunol.1402513
    1. Parsons PE, Eisner MD, Thompson BT, Mathay MA, Ancukiewicz M, Bernard GR, et al. . Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury. Crit Care Med. (2005) 33:1–6. 10.1097/01.CCM.0000149854.61192.DC
    1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. (2020) 395:497–506. 10.1016/S0140-6736(20)30183-5
    1. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. . Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. (2020) 30:269–71. 10.1038/s41422-020-0282-0
    1. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. . Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering. (2020). 10.1016/j.eng.2020.03.007. [Epub ahead of print].
    1. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. . Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. (2020) e200994. 10.1001/jamainternmed.2020.0994. [Epub ahead of print].
    1. Gao J, Tian Z, Yang Xu. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. (2020) 14:72–3. 10.5582/bst.2020.01047
    1. Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, et al. . A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res. (2020) 7:1–23. 10.1186/s40779-020-0233-6
    1. Her M, Kavanaugh A. Alterations in immune function with biologic therapies for autoimmune disease. J Allergy Clin Immunol. (2016) 137:19–27. 10.1016/j.jaci.2015.10.023
    1. He H, Jiang H, Chen Y, Ye J, Wang A, Wang C, et al. . Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity. Nat Commun. (2018) 9:2550. 10.1038/s41467-018-04947-6
    1. Juliana C, Fernandes-Alnemri T, Wu J, Datta P, Solorzano L, Yu JW, et al. . Anti-inflammatory compounds parthenolide and bay 11-7082 are direct inhibitors of the inflammasome. J Biol Chem. (2010) 285:9792–802. 10.1074/jbc.M109.082305
    1. Lamkanfi M, Mueller JL, Vitari AC, Misaghi S, Fedorova A, Deshayes K, et al. . Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J Cell Biol. (2009) 187:61–70. 10.1083/jcb.200903124
    1. Huang Y, Jiang H, Chen Y, Wang X, Yang Y, Tao J, et al. Tranilast directly targets NLRP 3 to treat inflammasome-driven diseases. EMBO Mol Med. (2018) 10:e8689 10.15252/emmm.201708689
    1. Leung YY, Yao Hui LL, Kraus VB. Colchicine – update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. (2015) 45:341–50. 10.1016/j.semarthrit.2015.06.013
    1. Misawa T, Takahama M, Kozaki T, Lee H, Zou J, Saitoh T, et al. . Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat Immunol. (2013) 14:454–60. 10.1038/ni.2550
    1. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. (2006) 440:237–41. 10.1038/nature04516
    1. Gorp HV, Saavedra PHV, De Vasconcelos NM, Van Opdenbosch N, Vande Walle L, Matusiak M, et al. . Familial Mediterranean fever mutations lift the obligatory requirement for microtubules in Pyrin inflammasome activation. Proc Natl Acad Sci USA. (2016) 113:14384–9. 10.1073/pnas.1613156113
    1. Park YH, Wood G, Kastner DL, Chae JJ. Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS. Nat Immunol. (2016) 17:914–21. 10.1038/ni.3457
    1. Robertson S, Martínez GJ, Payet CA, Barraclough JY, Celermajer DS, Bursill C, et al. . Colchicine therapy in acute coronary syndrome patients acts on caspase-1 to suppress NLRP3 inflammasome monocyte activation. Clin Sci. (2016) 130:1237–46. 10.1042/CS20160090
    1. Fernando S, Schwarz N, Williamson A, Toledo D, Zareh J, Di Dartolo B, et al. Anti-inflammatory effects of colchicine on oxidised low-density lipoproteins and cholesterol crystal-induced macrophage activation in vitro. Heart Lung Circul. (2017) 26:S69–70. 10.1016/j.hlc.2017.06.060
    1. Otani K, Watanabe T, Shimada S, Takeda S, Itani S, Higashimori A, et al. . Colchicine prevents NSAID-induced small intestinal injury by inhibiting activation of the NLRP3 inflammasome. Sci Rep. (2016) 6:32587. 10.1038/srep32587
    1. Daniels MJ, Rivers-Auty J, Schilling T, Spencer NG, Watremez W, Fasolino V, et al. . Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer's disease in rodent models. Nat Commun. (2016) 7:12504. 10.1038/ncomms12504
    1. Rothan HA, Bahrani H, Abdulrahman AY, Mohamed Z, Teoh TC, Othman S, et al. . Mefenamic acid in combination with ribavirin shows significant effects in reducing chikungunya virus infection in vitro and in vivo. Antiviral Res. (2016) 127:50–6. 10.1016/j.antiviral.2016.01.006
    1. Coll RC, Robertson AA, Chae JJ, Higgins SC, Munoz-Planillo R, Inserra MC, et al. A small molecule inhibitior of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. (2015) 21:248–55. 10.1038/nm.3806
    1. Jiang H, He H, Chen Y, Huang W, Cheng J, Ye J, et al. . Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. J Exp Med. (2017) 214:3219–38. 10.1084/jem.20171419
    1. Marchetti C, Swartzwelter B, Koenders MI, Azam T, Tengesdal IW, Powers N, et al. . NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of acute arthritis. Arthritis Res Ther. (2018) 20:169. 10.1186/s13075-018-1664-2
    1. Shim DW, Shin WY, Yu SH, Kim BH, Ye SK, Koppula S, et al. . BOT-4-one attenuates NLRP3 inflammasome activation: NLRP3 alkylation leading to the regulation of its ATPase activity and ubiquitination. Sci Rep. (2017) 7:15020. 10.1038/s41598-017-15314-8

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj